Barcelona-based venture capital firm Nina Capital has announced the launch of its €50M Fund III, aimed at supporting international founders developing need-driven healthcare solutions.
The fund will invest in companies focused on clinical innovation and education, healthcare infrastructure, and clinical pathways and health data.
With a geographic focus spanning Europe, North America, Israel, and Australia, Nina Capital plans to back startups from pre-seed to Series A, with investments ranging from €250,000 to €1.5M.
Key investors in Fund III include wealth management firm Seven Two Partners, professional family offices, foundations, corporations, and high-net-worth individuals from Europe and the United States.
Sifted reports that Nina Capital plans to back 25 startups, with 60 per cent based in Europe and the remaining 40 per cent primarily in the US. Fundraising began in September 2024, with a final close expected by the end of 2025. Nina Capital aims to acquire an 8-10 per cent stake in portfolio companies, with occasional higher ownership.
Brief about Nina Capital
Nina Capital is a global venture capital firm focused on driving healthcare transformation through information technology.
Specialising in pre-seed and seed-stage investments, it supports founders with industry expertise who develop innovative solutions in engineering, data science, and IT-enabled healthcare.
The firm applies the Stanford-developed Biodesign methodology, which reduces risk in healthcare innovation through a need-driven, value-based approach. Nina Capital has invested in 50 companies across nearly 20 countries since 2019, impacting over 10 million lives.
01
How Gen Z affects B2B social media